Eloralintide (LY3841136): Eli Lilly's amylin agonist
In short: Eloralintide (code LY3841136) is an amylin analog developed by Eli Lilly. It primarily activates the AMY1 amylin receptor and is administered subcutaneously once weekly in trials. In phase 2 (263 adults, 48 weeks, The Lancet(2025), the average weight loss has reached 20 % at the highest dose, compared to 0.4% under placebo. Eight phase 3 trials are underway or in preparation, and no marketing authorization exists to date.
What is eloralintide?
Eloralintide (international nonproprietary name; development code LY3841136) is an investigational peptide from Eli Lilly, the company behind tirzepatide and retatrutide. It is a synthetic analog of human amylin, a 37-amino-acid hormone that is released by the beta cells of the pancreas along with insulin after meals, and which plays a role in the satiety signal.
Native amylin is poorly suited to research: it readily forms unstable fibrils and has a short duration of action. Pramlintide, the first amylin analog, must be injected two to three times a day. Like Novo Nordisk's cagrilintide, eloralintide was designed to be stable and effective for a full week. Lilly is developing it for the treatment of obesity, both alone and in combination with tirzepatide.
According to the Lilly team that developed it (Briere et al., 2025), eloralintide retains a chain of 37 amino acids, including 3 non-coding amino acids (positions 11, 15, and 22). The disulfide bridge of native amylin is replaced by a more chemically stable methylene thioacetal bridge. A 20-carbon fatty acid diacid, attached to lysine 26 by a link of two glutamic acid residues, allows it to bind to blood albumin: this is what prolongs its duration of action. After a single dose, its terminal half-life, measured in phase 1, ranges from 12.9 to 15.3 days. The complete sequence is not published.
Mechanism: Amylin, another pathway than GLP-1
Amylin receptors are assemblies: the calcitonin receptor (CTR) associated with one of the RAMP proteins, resulting in the AMY1, AMY2 and AMY3 receptors. Their activation, especially in the brainstem (area postrema) and hypothalamus, reduces food intake and slows gastric emptying.
Eloralintide is not not It is a GLP-1 agonist. It acts on a different family of receptors than semaglutide, tirzepatide, or retatrutide. This is why Lilly is also studying it in combination with tirzepatide: the two mechanisms can be additive rather than overlapping.
What does "selective" mean?
Cagrilintide is an agonist non-selective It activates AMY1, AMY3, and the calcitonin receptor with comparable potency. Eloralintide, on the other hand, primarily activates AMY1. In human cells, it is approximately 12 times more powerful on AMY1 than on the calcitonin receptor, and 11 times more than on AMY3 (Briere et al., 2025).
In rats, eloralintide induced less conditioned food aversion than cagrilintide, with comparable fat mass loss and less lean mass loss. Lilly hypothesizes that this results in better gastrointestinal tolerance. The authors themselves note that no "useful" selectivity threshold has been established, and no clinical trial has directly compared the two molecules.
Published results: from phase 1 to phase 2
Phase 1, single dose: 48 healthy volunteers
In the first trial (NCT05295940), 48 healthy volunteers received a single injection of 0.04 to 12 mg, or a placebo. Four weeks later, weight had decreased by 2.5% after 4 mg and by 4.4% after 12 mg, compared to an increase of 0.6% with placebo. Of 16 adverse events, 15 were mild. The pharmacokinetic profile is consistent with once-weekly administration (Briere et al., 2025).
Phase 1, repeated doses for 12 weeks: 100 participants
One hundred overweight or obese individuals received one injection per week for 12 weeks, without a gradual increase in dose. Average weight loss ranged from 2.6% to 11.3% depending on the group. The most frequent side effects were decreased appetite (19%), headaches (12%), and fatigue (11%). Digestive disorders remained infrequent: diarrhea 10%, nausea 8%, vomiting 4% (Bhattachar et al., 2026).
Phase 2: 263 adults for 48 weeks
The phase 2 trial (NCT06230523), published in The Lancet In December 2025, a study included 263 adults from 46 US centers: obese (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition, and without type 2 diabetes. The mean age was 49 years, mean weight 109 kg, mean BMI 39.1, and 78% were women. Each group received one injection per week: a fixed dose, a dose-increasing dose, or a placebo.
| Test group | Average weight loss at 48 weeks | Nausea | Fatigue |
|---|---|---|---|
| Placebo | -0.4% | 14 % | 12 % |
| 1 mg | -9% | 11 % | 0 % |
| 3 mg | -12% | 13 % | 13 % |
| 6 mg | -18% | 64 % | 29 % |
| 9 mg | -20% | 33 % | 43 % |
| 6 → 9 mg | -20% | 54 % | 46 % |
| 3 → 9 mg | -16% | 25 % | 21 % |
Estimate of "efficacy," which assumes that participants followed the treatment. Source: Billings et al., The Lancet, 2025.
Weight loss increases with the dose. Nausea also increases, with large differences between groups: 64% in the group receiving 6 mg initially, compared to 25% in the group where the dose was increased gradually from 3 mg. Fatigue is another common side effect. The authors conclude that there was clinically significant weight loss and overall good tolerability.
With tirzepatide: EloraTZP (phase 2)
On September 30, 2026, Lilly published the results of a 48-week Phase 2 trial, presented at the European Association for Diabetes Society (EASD) congress, in 367 obese or overweight adults with type 2 diabetes. The strongest combination (eloralintide 9 mg and tirzepatide 15 mg) resulted in up to 23,3 % Weight loss was higher in the combined regimen, compared to 14.8% for tirzepatide 15 mg alone, with a decrease in HbA1c of up to 2.9 points versus 2.4. Discontinuations due to adverse effects ranged from 10.8% to 27% depending on the combination, compared to 2.9% with tirzepatide alone, primarily for gastrointestinal issues. As of November 15, 2026, these results are only available through the press release and the congress proceedings; no articles are indexed in PubMed.
Phase 3: the ENLIGHTEN and AMPLIFY programs
Lilly launched the phase 3 ENLIGHTEN program for eloralintide alone at the end of 2025, followed by AMPLIFY for the combination with tirzepatide. Here are the eight trials registered on ClinicalTrials.gov as of November 15, 2026:
| Trial | Study population | Expected participants | Status | Main end estimated |
|---|---|---|---|---|
| ENLIGHTEN-1 NCT07321886 |
Obesity or overweight, without type 2 diabetes | 1 980 | Recruitment in progress | March 2028 |
| ENLIGHTEN-2 NCT07282600 |
Obesity or overweight with type 2 diabetes | 1 035 | Recruitment in progress | January 2028 |
| ENLIGHTEN-3 NCT07369011 |
Obstructive sleep apnea and obesity or overweight | 800 | Recruitment in progress | March 2028 |
| ENLIGHTEN-4 NCT07353931 |
Knee osteoarthritis pain and obesity or being overweight | 900 | Recruitment in progress | March 2028 |
| ENLIGHTEN-6 NCT07392190 |
Persistent obesity despite weekly incretin | 900 | Recruitment in progress | June 2028 |
| ENLIGHTEN-10 NCT07900633 |
Type 2 diabetes and high cardiovascular risk | 3 000 | Not yet open | November 2029 |
| AMPLIFY-1 NCT07881432 |
EloraTZP, obesity or overweight without type 2 diabetes | 2 115 | Not yet open | October 2029 |
| AMPLIFY-2 NCT07881458 |
EloraTZP, obesity or overweight with type 2 diabetes | 1 000 | Recruitment began on 16/10/2026 | October 2029 |
The first phase 3 results are therefore not expected before 2028. Lilly is also testing eloralintide with another of its molecules, macupatide (LY3532226), in two phase 2 trials (NCT07215559 and NCT07589608).
Eloralintide vs cagrilintide, retatrutide and tirzepatide
The table places eloralintide among similar molecules. The figures come from different trials (populations, durations, methods): it is not a direct comparison.
| Molecule | Laboratory | Targeted receptors | Pace | Reference published weight loss | Stadium (Nov. 2026) |
|---|---|---|---|---|---|
| Eloralintide | Eli Lilly | Amylin (AMY1 preferred) | Weekly | −20% at 48 weeks. (phase 2, 9 mg) | Phase 3 (ENLIGHTEN) |
| Cagrilintide | Novo Nordisk | Amylin and calcitonin (non-selective) | Weekly | −10.8% at 26 weeks. (phase 2, 4.5 mg) | With semaglutide (CagriSema): application submitted to the FDA in December 2025 |
| Retatrutide | Eli Lilly | GLP-1, GIP and glucagon | Weekly | −24.2% at 48 weeks. (phase 2, 12 mg) | Phase 3 (TRIUMPH) |
| Tirzepatide | Eli Lilly | GLP-1 and GIP | Weekly | −20.9% at 72 weeks. (phase 3 SURMOUNT-1, 15 mg) | Approved as a medicine |
Over the same 48-week period, the phase 2 results for eloralintide alone (−20%) remained lower than those for retatrutide (−24.2%) in a different trial. Its advantage lies elsewhere: it uses a different mechanism of action than incretins, hence its study in combination (EloraTZP) and in individuals whose obesity persists despite incretin therapy (ENLIGHTEN-6). For the other amylin analog, see our comparison. retatrutide vs cagrilintide.
What we don't yet know
- No results from phase 3. The published data relates to 148 people in phase 1 and 263 in phase 2.
- The real contribution of selectivity. The digestive benefit has been shown in rats; in phase 2 trials, nausea affected up to 64% of one group. No trials directly compare eloralintide to cagrilintide.
- The duration of the effect. Weight changes beyond 48 weeks, and after stopping treatment, are not published.
- Type 2 diabetes. The published phase 2 excluded diabetic individuals; the only data in this population comes from the EloraTZP press release, pending ENLIGHTEN-2.
- The complete structure. The exact sequence of the molecule is not published.
Eloralintide at MyPeptide
Eloralintide is not yet listed in the MyPeptide catalog. For amylin pathway research, Cagrilintide 5 mg is available with its verifiable Janoshik analysis report. For incretin agonists, see our retatrutide formulations.
Frequently Asked Questions about Eloralintide
What is eloralintide?
Eloralintide (code LY3841136) is an amylin analog developed by Eli Lilly. It primarily activates the AMY1 amylin receptor and is administered subcutaneously once weekly in clinical trials. It is in phase 3 clinical trials for the treatment of obesity, both alone and in combination with tirzepatide.
What weight loss has eloralintide shown?
In the phase 2 trial published in The Lancet (2025), the average weight loss at 48 weeks ranged from 9% in the 1 mg group to 20% in the 9 mg group, compared to 0.4% in the placebo group, in 263 adults without diabetes. These are clinical trial averages, not a guarantee of individual results.
What is the difference between eloralintide and cagrilintide?
Both are amylin analogs administered once weekly. Cagrilintide (Novo Nordisk) also activates the calcitonin receptor with comparable potency; eloralintide (Eli Lilly) primarily activates the AMY1 receptor, and its half-life, as measured in phase 1 trials, is approximately two weeks. No trials have directly compared them.
Eloralintide or retatrutide: what's the difference?
Retatrutide activates three receptors (GLP-1, GIP, and glucagon); eloralintide acts on a different family, the amylin receptors. In phase 2, over 48 weeks, retatrutide showed a 24.2% reduction and eloralintide a 20% reduction, in two separate trials that are not directly comparable.
Is eloralintide approved as a drug?
No. As of November 15, 2026, eloralintide has not been approved for marketing in any country. The phase 3 ENLIGHTEN trials are ongoing, and the first trials are expected to be completed in 2028, according to ClinicalTrials.gov.
What is EloraTZP?
EloraTZP is the combination of eloralintide and tirzepatide being studied by Lilly. In phase 2 trials, in 367 adults with type 2 diabetes, it resulted in up to 23.3% weight loss at 48 weeks, compared to 14.8% for tirzepatide alone, according to Lilly's press release of September 30, 2026. Two phase 3 trials, AMPLIFY-1 and AMPLIFY-2, have been launched.
What side effects have been reported?
Nausea and fatigue were the main side effects. In phase 2, nausea varied considerably between groups: 64% in the group receiving 6 mg initially, 25% in the group where the dose was gradually increased from 3 mg, and 14% in the placebo group. Fatigue affected up to 46% of one group.
Is there a dosage for eloralintide?
No. No dosage is validated outside of clinical trials. The doses mentioned in this article are the groups used in published trials, not a recommendation. MyPeptide does not provide dosage information: its products are intended exclusively for scientific research.
Key points to remember
- Eloralintide (LY3841136) is an amylin analog from Eli Lilly, which preferentially activates the AMY1 receptor.
- One injection per week in the trials, with a half-life of approximately two weeks
- Phase 2: -20% weight loss at 48 weeks At best, nausea and fatigue are the most frequent side effects.
- Combined with tirzepatide (EloraTZP): up to 23.3% in people with diabetes, according to Lilly's press release
- Eight phase 3 trials (ENLIGHTEN, AMPLIFY), first results not expected before 2028; no marketing authorization yet
Sources
- Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. Lancet. 2025 · PMID 41207310
- Bhattachar S et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026 · PMID 41559929
- Briere DA et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab. 2025 · PMID 41109426
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity (phase 2). Lancet. 2021 · PMID 34798060
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023 · PMID 37366315
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022 · PMID 35658024
- Eli Lilly, press release of September 30, 2026: Phase 2 results of EloraTZP (eloralintide and tirzepatide). investor.lilly.com
- ClinicalTrials.gov registry: Phase 2 trial NCT06230523 and Phase 3 trials listed above. NCT06230523
Changelog: November 15, 2026, publication.
📦 Amylin research at MyPeptide
Cagrilintide 5 mg · All GLP peptides • Verifiable Janoshik analysis reports • Delivery in 2 to 5 business days in Europe

